Landscape Capital Management L.L.C. Acquires 23,086 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Landscape Capital Management L.L.C. grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 85.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,986 shares of the company’s stock after purchasing an additional 23,086 shares during the period. Landscape Capital Management L.L.C.’s holdings in Apellis Pharmaceuticals were worth $1,595,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Cinctive Capital Management LP acquired a new position in shares of Apellis Pharmaceuticals during the 4th quarter worth approximately $2,776,000. Trexquant Investment LP acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at $6,478,000. Geode Capital Management LLC raised its stake in Apellis Pharmaceuticals by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock valued at $58,699,000 after purchasing an additional 28,426 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of Apellis Pharmaceuticals by 266,361.5% during the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock worth $44,214,000 after acquiring an additional 1,385,080 shares during the period. Finally, Pictet Asset Management Holding SA increased its stake in shares of Apellis Pharmaceuticals by 16.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 347,854 shares of the company’s stock valued at $11,100,000 after purchasing an additional 49,901 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. The Goldman Sachs Group cut their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Royal Bank of Canada decreased their price objective on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a report on Monday, March 3rd. Scotiabank upped their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $45.59.

Apellis Pharmaceuticals Price Performance

APLS opened at $19.97 on Friday. The business has a fifty day moving average of $26.22 and a 200 day moving average of $29.05. The stock has a market cap of $2.51 billion, a P/E ratio of -9.84 and a beta of 0.85. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.76 and a 52-week high of $57.85.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. During the same period in the prior year, the business posted ($0.73) earnings per share. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 2,824 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the transaction, the chief executive officer now directly owns 415,695 shares in the company, valued at $12,271,316.40. This represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,054 shares of company stock valued at $1,952,719. 6.80% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).